Sands Capital Ventures’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Sands Capital Ventures’s Portfolio DICE Stock Details DICE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,748,970	Closed	-$78.8M	–	23
2023 Q1	$78.8M	Hold	2,748,970	–	–	19.47%	1
2022 Q4	$85.8M	Sell	2,748,970 -400,000	-13%	-$13M	23.49%	1
2022 Q3	$63.9M	Hold	3,148,970	–	–	18.56%	1
2022 Q2	$48.9M	Hold	3,148,970	–	–	13.42%	2
2022 Q1	$60.2M	Hold	3,148,970	–	–	12.59%	4
2021 Q4	$79.7M	Hold	3,148,970	–	–	11.81%	4
2021 Q3	$103M	Buy	+3,148,970	New	+$107M	15.55%	3

Other funds holding DICE

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Sands Capital Ventures's DICE Position: Q2 2023 in Review

Sands Capital Ventures sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q2 2023, closing a stake of 2,748,970 shares — an estimated $78.8M sold.

Sands Capital Ventures first reported a position in DICE in Q3 2021 and held it in 7 quarters. The position peaked at $103M in Q3 2021. 160 funds tracked by Wall St. Rank hold DICE as of Q2 2023.

Sands Capital Ventures reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Sands Capital Ventures sold 2,748,970 DICE Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $78.8M.
Sands Capital Ventures first reported a position in DICE Therapeutics, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
Sands Capital Ventures's DICE Therapeutics, Inc. Common Stock position peaked at $103M in Q3 2021.
160 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Sands Capital Ventures's 13F filing for Q2 2023, filed 15 Aug 2023.